Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: The cope study

American Journal of Respiratory and Critical Care Medicine

Volumn 166, Issue 10, 2002, Pages 1358-1363

  Van Valk, Paul Der ^a,b   Monninkhof, Evelyn ^a,b   Van Palen, Job Der ^a,b   Zielhuis, Gerhard ^a,b   Van Herwaarden, Cees ^a,b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

COPD; Exacerbations; Health related quality of life; Inhaled corticosteroids

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; SAINT GEORGE RESPIRATORY QUESTIONNAIRE; VITAL CAPACITY;

EID: 0037111198     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200206-512OC     Document Type: Article

References (34)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276.
2. World Health Organization. The World Health Report. Life in the 21st Century. A Vision for all. Geneva: World Health Organization; 1998.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020. Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
4. World Health Organization. World Health Report. Geneva: World Health Organization; 2000. Available at: http://www.who.int/whr/2000/en/statistics.htm
5. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV. The Lung Health Study. JAMA 1994; 272:1497-1505.
6. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Thorax 1998; 53:137-147.
7. Calverley PM. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:341-342.
8. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:342-344.
9. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155:542-548.
10. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269-280.
11. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159:941-955.
12. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343:1902-1909.
13. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000; 320:1297-1303.
14. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease: International COPD Study Group. Lancet 1998; 351:773-780.
15. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:580-584.
16. Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53:477-482.
17. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340:1948-1953.
18. Vestbo J. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999; 353:1819-1823.
19. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999; 93:161-166.
20. O'Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, Sherman C, Rounds S. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001; 164:365-371.
21. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:s77-s120.
22. Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koeter GH, Dekhuijzen PN, Sluiter HJ. Interpretation of bronchodilator response in patients with obstructive airways disease: The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax 1992; 47:429-436.
23. Pieterse ME, Seydel ER, DeVries H, Mudde AN, Kok GJ. Effectiveness of a minimal contact smoking cessation program for Dutch general practitioners: A randomized controlled trial. Prev Med 2001; 32:182-190.
24. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
25. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows: Official statement of the European Respiratory Society. Eur Respir J 1993; 6:5-40.
26. Wilson RC, Jones PW. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci 1989; 76:277-282.
27. Sciurba FC, Slivka WA. Six-minute walk testing. Semin Resp Crit Care Med 1998; 19:383-392.
28. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: The Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155:1278-1282.
29. Piantadosi P. Sample size and power. In: Piantadosi S, editor. Clinical Trials. New York: John Wiley & Sons, Inc.; 1997. p. 148-185.
30. SAS Institute. Release 6.12. Cary, NC: SAS In.; 1996.
31. SPSS for Windows. Release 10. Chicago IL: SPSS In.; 2001.
32. Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995; 107:187S-193S.
33. Spencer S, Calverley PM, Sherwood BP, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:122-128.
34. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1418-1422.